ACTRN12623001317684已完成1 期
An open-label Phase 1 study to investigate the pharmacokinetics, safety and tolerability, and pharmacodynamics of nicotine administered in single and multiple inhalations via a novel Miist Nicotine Inhaler in healthy male smokers
Miist Therapeutics South Pty Ltd0 个研究点目标入组 10 人开始时间: 2023年12月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •1.Male between 18 and 55 years of age, inclusive.
- •2.Cigarette smoker who smokes more than 10 cigarettes (tobacco cigarettes alone or in combination with e-cigarettes) a day and who has smoked for 1 year.
- •3.Able to abstain from smoking and use of other nicotine containing products (e.g., gum, patches or any other Nicotine Replacement Treatment product) for 12 hours prior to study dosing and for the duration of confinement in the Clinical Research Unit.
- •4.Have a Fagerström Test for Nicotine Dependence (FTND) score of at least 4.
- •5.Body weight above 50 kg and body mass index (BMI) in the range 19 to 35 kg per m2 (inclusive).
- •6.Willing and able to have an arterial line inserted and maintained for blood sampling for PK.
- •7.Healthy as determined by a licensed and experienced physician, based on a medical evaluation including medical history, physical examination, safety laboratory tests and cardiac monitoring. A potential participant with a clinical abnormality or laboratory parameters outside the normal reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. The Investigator may discuss with the local MM and Sponsor representative as required.
- •8.Estimated glomerular filtration rate (eGFR) must be above 60 mL per min per 1.73 m2 (calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula).
- •9.Normal standard 12-lead ECG parameters after at least 5 minutes resting in supine position
- •10.Normal vital signs after at least 5 minutes resting semi-supine:
- •11.Must agree to abstain from heterosexual intercourse for at least 12 hours following discharge from the Clinical Research Unit.
- •12.Provides written informed consent and is willing and able to undergo all study procedures and participate in the scheduled follow up teleconference call per protocol.
排除标准
- •1.Known or suspected history of allergy or sensitivity to nicotine or any other component of the inhaler.
- •2.A history of Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV) infection and/or a positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- •3.History of confirmed chronic and/or serious pulmonary disease, including asthma, or chronic obstructive pulmonary disease, a history of myocardial infarction or cerebrovascular accident, other clinically significant cardiac, liver or renal conditions, or any comorbidity that could place them at risk or interfere with the interpretation of the study data.
- •4.Participant with a diagnosed bleeding disorder or significant bruising or bleeding difficulties with blood draws or is unable to provide a blood sample without undue trauma or distress or has poor peripheral arterial and/or venous access.
- •5.Any other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or IP administration or may interfere with the interpretation of trial results and, in the judgement of the Investigator or Sponsor, would make the participant inappropriate for entry into this trial.
- •6.Participant requiring any inhaled or anti-coagulant medications.
- •7.Inability to use the Miist Nicotine Inhaler correctly following training.
- •8.A positive pre-study drug or alcohol screen.
- •9.History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of more than 21 units for males.
- •10.Participation in a clinical trial within 30 days before dosing; use of any experimental therapy within 30 days or 5 half-lives prior to dosing, whichever is greater; or use of any biologic therapy within 12 weeks or 5 half-lives prior to dosing, whichever is greater.
- •11.Participant unable to provide written informed consent or participant under guardianship.
- •12.Unwilling or unable to follow protocol requirements.
研究者
相似试验
撤回
不适用
A Phase I, open-label study to investigate the pharmacokinetics of GLPG2451 given as two doses of a capsule formulation in healthy subjectsCystic fibrosismucoviscidosisNL-OMON45502Galapagos SAS12
已完成
不适用
A Phase I, open-label trial to investigate the pharmacokinetic interaction between TMC125 and two antifungal agents (fluconazole and voriconazole), all at steady-state in healthy subjects.AIDSHIV10021460NL-OMON32571Tibotec Pharmaceuticals Ltd, EastGate Village, Eastgate, Little Island, CO Cork, Ireland, In Nederland vertegenwoordigd door Janssen-Cilag B.V.18
进行中（未招募）
1 期
Research done in healthy human volunteers to Investigate how the MK-8342B (ENG-E2, 125/300 µg/day) Vaginal Ring behaves in and influences the body of female Postmenarcheal Adolescents and Healthy Female Adults.Hormonal contraception and primary dysmenorrhea in woman seeking contraception.MedDRA version: 19.0Level: LLTClassification code 10073728Term: Hormonal contraceptionSystem Organ Class: 100000004865EUCTR2015-005284-16-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
已完成
不适用
A Phase I, Open-Label Study to Investigate the Pharmacodynamics and Pharmacokinetics of Etonogestrel (ENG) and 17*-Estradiol (E2) in Healthy Young Adult Women Following Administration of MK-8342B (ENG-E2, 125/300 *g/day) Vaginal Ring for an Extended Period of Timedysmenorrheahormonal contraception and primary dysmenorrhea in womencontraceptionNL-OMON43028Merck Sharp & Dohme (MSD)20
已完成
不适用
An open label, single dose study to assess the pharmacokinetics of a microdose of recombinant human placental alkaline phosphatase (hRESCAP, part 1) followed by a randomized, double-blind, placebo-controlled, parallel, single ascending dose, first-in-human study to assess safety and tolerability of hRESCAP (part 2) in healthy male volunteersinflammation1000381610004018NL-OMON38993Centre for Human Drug Research15